A Randomized Phase <scp>II</scp> Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde

Open source

DOI: 10.1002/ajh.70403
Published: 2026-06-12
Container: American Journal of Hematology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ajh.70403,
  title = {A Randomized Phase
                    <scp>II</scp>
                    Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma},
  author = {Julio C. Chavez and Mariana Bastos‐Oreiro and Catherine Diefenbach and Izidore S. Lossos and Nirav Shah and Sarit Assouline and Adam J. Olszewski and Seema Naik and Nilanjan Ghosh and Song Pham and Michael C. Wei and Connie Batlevi and Iris To and Wahib Ead and Sneha Makadia and Elicia Penuel and Jing Jing and Lihua E. Budde},
  year = {2026},
  journal = {American Journal of Hematology},
  doi = {10.1002/ajh.70403},
  url = {https://doi.org/10.1002/ajh.70403}
}

RIS

TY  - JOUR
TI  - A Randomized Phase
                    <scp>II</scp>
                    Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma
AU  - Julio C. Chavez
AU  - Mariana Bastos‐Oreiro
AU  - Catherine Diefenbach
AU  - Izidore S. Lossos
AU  - Nirav Shah
AU  - Sarit Assouline
AU  - Adam J. Olszewski
AU  - Seema Naik
AU  - Nilanjan Ghosh
AU  - Song Pham
AU  - Michael C. Wei
AU  - Connie Batlevi
AU  - Iris To
AU  - Wahib Ead
AU  - Sneha Makadia
AU  - Elicia Penuel
AU  - Jing Jing
AU  - Lihua E. Budde
PY  - 2026
JO  - American Journal of Hematology
DO  - 10.1002/ajh.70403
UR  - https://doi.org/10.1002/ajh.70403
ER  -

APA

Chavez, J. C., Bastos‐Oreiro, M., Diefenbach, C., Lossos, I. S., Shah, N., Assouline, S., Olszewski, A. J., Naik, S., Ghosh, N., Pham, S., Wei, M. C., Batlevi, C., To, I., Ead, W., Makadia, S., Penuel, E., Jing, J., & Budde, L. E. (2026). A Randomized Phase <scp>II</scp> Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma. American Journal of Hematology. https://doi.org/10.1002/ajh.70403

Source records

crossref · retrieved 2026-09-25T11:00:25.197Z